Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | EPOR | P19235 | 5/20 | 0.36 |
| ▸ | BMP1 | P13497 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.33 |
| ▸ | CHRNG | P07510 | 2/20 | 0.33 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.33 |
| ▸ | CHRND | Q07001 | 2/20 | 0.33 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6892894 | 0.94 | SMN1; SMN2 (0.39) | SMN1; SMN2AVPR1BHPGDMEN1KMT2A | |
| SCHEMBL7676093 | 0.89 | SMN1; SMN2 (0.34) | SMN1; SMN2AVPR1BHPGDMEN1KMT2A | |
| SCHEMBL4653743 | 0.87 | SMN1; SMN2 (0.42) | SMN1; SMN2HPGDMEN1KMT2AEPOR | |
| SCHEMBL14271452 | 0.87 | SMN1; SMN2 (0.42) | SMN1; SMN2HPGDMEN1KMT2AEPOR | |
| SCHEMBL6889607 | 0.85 | SMN1; SMN2 (0.35) | SMN1; SMN2AVPR1BHPGDMEN1KMT2A | |
| SCHEMBL4957686 | 0.82 | MMP2 (0.46) | SMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL24136485 | 0.82 | CA1 (0.42) | SMN1; SMN2HPGDMEN1KMT2ABMP1 | |
| SCHEMBL17911909 | 0.82 | CA1 (0.42) | SMN1; SMN2HPGDMEN1KMT2ABMP1 | |
| SCHEMBL8313275 | 0.82 | CA1 (0.42) | SMN1; SMN2HPGDMEN1KMT2ABMP1 | |
| Trifluoroacetic Acid SCHEMBL2274359 | 0.80 | L3MBTL1 (0.41) | HPGDMEN1KMT2ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020041878-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS MEDICAL IMAGING, INC. | 2002-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020041878-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | SMN1; SMN2 4074/4885AVPR1B 656/4885HPGD 1448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.